"Virginia Cancer Specialists offers a dedicate team of medical oncologists, hematologists, oncology nurses, oncology pharmacists and a research department, all working on your behalf to provide comprehsensive, advanced cancer care in your community."

During the past decade, NEXT Oncology - Virginia Cancer Specialists conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "NEXT Oncology - Virginia Cancer Specialists" #1 sponsor was "HiFiBiO Therapeutics" with 2 trials, followed by "Astellas Pharma Inc" with 1 trials sponsored, "Nuvalent Inc." with 1 trials sponsored, "OncoC4, Inc." with 1 trials sponsored and "Orum Therapeutics USA, Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "NEXT Oncology - Virginia Cancer Specialists" #1 collaborator was "National Cancer Institute (NCI)" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "NEXT Oncology - Virginia Cancer Specialists" are "Cervical Cancer" (2 trials), "Gastric Cancer" (2 trials), "Head and Neck Squamous Cell Carcinoma" (2 trials), "Non Small Cell Lung Cancer" (2 trials) and "Renal Cell Carcinoma" (2 trials). Many other conditions were trialed in "NEXT Oncology - Virginia Cancer Specialists" in a lesser frequency.

Most popular intervention types in "NEXT Oncology - Virginia Cancer Specialists" are "Drug" (6 trials). Other intervention types were less common.

The name of intervention was led by "ASP3082" (1 trials), "Cetuximab" (1 trials), "HFB200301" (1 trials), "HFB301001" (1 trials) and "NVL-520" (1 trials). Other intervention names were less common.

The vast majority of trials in "NEXT Oncology - Virginia Cancer Specialists" are 6 trials for "All" genders.

Currently, there are NaN active trials in "NEXT Oncology - Virginia Cancer Specialists". undefined are not yet recruiting, 6 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in NEXT Oncology - Virginia Cancer Specialists, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in NEXT Oncology - Virginia Cancer Specialists, 6 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".